Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTACDR1614

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	NOV 21	CAS patent coverage to include exemplified prophetic substances identified in English-, French-, German-, and Japanese-language basic patents from 2004-present
NEWS 3	NOV 26	MARPAT enhanced with FSORT command
NEWS 4	NOV 26	CHEMSAFE now available on STN Easy
NEWS 5	NOV 26	Two new SET commands increase convenience of STN searching
NEWS 6	DEC 01	ChemPort single article sales feature unavailable
NEWS 7	DEC 12	GBFULL now offers single source for full-text coverage of complete UK patent families
NEWS 8	DEC 17	Fifty-one pharmaceutical ingredients added to PS
NEWS 9	JAN 06	The retention policy for unread STNmail messages will change in 2009 for STN-Columbus and STN-Tokyo
NEWS 10	JAN 07	WPIDS, WPINDEX, and WPIX enhanced Japanese Patent Classification Data
NEWS 11	FEB 02	Simultaneous left and right truncation (SLART) added for CERAB, COMPUAB, ELCOM, and SOLIDSTATE
NEWS 12	FEB 02	GENBANK enhanced with SET PLURALS and SET SPELLING
NEWS 13	FEB 06	Patent sequence location (PSL) data added to USGENE
NEWS 14	FEB 10	COMPENDEX reloaded and enhanced
NEWS 15	FEB 11	WTEXTILES reloaded and enhanced
NEWS 16	FEB 19	New patent-examiner citations in 300,000 CA/CAplus patent records provide insights into related prior art
NEWS 17	FEB 19	Increase the precision of your patent queries -- use terms from the IPC Thesaurus, Version 2009.01
NEWS 18	FEB 23	Several formats for image display and print options discontinued in USPATFULL and USPAT2
NEWS 19	FEB 23	MEDLINE now offers more precise author group fields and 2009 MeSH terms
NEWS 20	FEB 23	TOXCENTER updates mirror those of MEDLINE - more precise author group fields and 2009 MeSH terms
NEWS 21	FEB 23	Three million new patent records blast AEROSPACE into STN patent clusters
NEWS 22	FEB 25	USGENE enhanced with patent family and legal status display data from INPADOCDB
NEWS 23	MAR 06	INPADOCDB and INPAFAMDB enhanced with new display formats
NEWS 24	MAR 11	EPFULL backfile enhanced with additional full-text applications and grants
NEWS 25	MAR 11	ESBIOBASE reloaded and enhanced
NEWS 26	MAR 20	CAS databases on STN enhanced with new super role for nanomaterial substances
NEWS 27	MAR 23	CA/CAplus enhanced with more than 250,000 patent equivalents from China

```
 NEWS 28  MAR 30  IMSPATENTS reloaded and enhanced
 NEWS 29  APR 03  CAS coverage of exemplified prophetic substances
                  enhanced

 NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
              AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN customer
  agreement.  This agreement limits use to scientific research.  Use
  for software development or design, implementation of commercial
  gateways, or use of CAS and STN data in the building of commercial
  products is prohibited and may result in loss of user privileges
  and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 11:20:01 ON 06 APR 2009

=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.22       0.22

FILE 'REGISTRY' ENTERED AT 11:20:26 ON 06 APR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    5 APR 2009  HIGHEST RN 1132636-28-2
DICTIONARY FILE UPDATES:   5 APR 2009  HIGHEST RN 1132636-28-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\STNEXP\Queries\10598826s3.str
```





```
chain nodes :
7  8  9  10  11  12
ring nodes :
1  2  3  4  5  6
chain bonds :
5-10  6-7  7-8  7-9  10-11  10-12
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6
exact/norm bonds :
7-8  7-9  10-11
exact bonds :
5-10  6-7  10-12
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6


Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:CLASS  8:CLASS  9:CLASS  10:CLASS
 11:CLASS  12:CLASS



L1      STRUCTURE UPLOADED

=> s l1
SAMPLE SEARCH INITIATED 11:20:39 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     2302 TO ITERATE

 86.9% PROCESSED     2000 ITERATIONS                                50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:        43162 TO    48918
PROJECTED ANSWERS:            1957 TO     3337

L2           50 SEA SSS SAM L1

=> s l1 sss sam
SAMPLE SEARCH INITIATED 11:20:49 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     2302 TO ITERATE
```

```
 86.9% PROCESSED     2000 ITERATIONS                              50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:        43162 TO    48918
PROJECTED ANSWERS:            1957 TO     3337

L3           50 SEA SSS SAM L1

=> s l1 sss full
FULL SEARCH INITIATED 11:20:54 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    44194 TO ITERATE

100.0% PROCESSED    44194 ITERATIONS                            2785 ANSWERS
SEARCH TIME: 00.00.02

L4         2785 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                              SINCE FILE      TOTAL
                                                      ENTRY    SESSION
FULL ESTIMATED COST                                  185.88     186.10

FILE 'CAPLUS' ENTERED AT 11:20:59 ON 06 APR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 6 Apr 2009  VOL 150 ISS 15
FILE LAST UPDATED: 5 Apr 2009  (20090405/ED)

Caplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> s l4
L5         2130 L4

=> s l4 and cerbral
           2130 L4
              7 CERBRAL
L6            0 L4 AND CERBRAL
```

```
=> s l4 and ischemia
          2130 L4
         88516 ISCHEMIA
            78 ISCHEMIAS
         88532 ISCHEMIA
                  (ISCHEMIA OR ISCHEMIAS)
L7           12 L4 AND ISCHEMIA

=> d ibib abs hitstr 1-12

L7   ANSWER 1 OF 12  CAPLUS  COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:         2007:1176119  CAPLUS
DOCUMENT NUMBER:          147:462304
TITLE:                    Spirocyclic heterocyclic derivatives and methods of
                          their use
INVENTOR(S):              Dolle, Roland E.; Lebourdonnec, Bertrand; Chu, Guo-Hua
PATENT ASSIGNEE(S):       Adolor Corporation, USA
SOURCE:                   PCT Int. Appl., 127pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
     WO 2007118151         A2    20071018    WO 2007-US66071         20070405
     WO 2007118151         A3    20080703
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA,
             CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB,
             GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM,
             KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK,
             MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO,
             RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT,
             TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,
             GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
             BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA
     US 20070269374        A1    20071122    US 2007-696585          20070404
     AU 2007234762         A1    20071018    AU 2007-234762          20070405
     CA 2648287            A1    20071018    CA 2007-2648287         20070405
     EP 2001467            A2    20081217    EP 2007-760193          20070405
         R:  AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR,
             AL, BA, HR, MK, RS
     IN 2008DN08019        A     20081107    IN 2008-DN8019          20080924
     KR 2009014157         A     20090206    KR 2008-727224          20081106
PRIORITY APPLN. INFO.:                       US 2006-790416P     P   20060406
                                             US 2007-696585      A   20070404
                                             WO 2007-US66071     W   20070405
OTHER SOURCE(S):          MARPAT 147:462304
AB   Spirocyclic heterocyclic derivs., pharmaceutical compns. containing these
     compds., and methods for their pharmaceutical use are disclosed.  In
     certain embodiments, the spirocyclic heterocyclic derivs. are ligands of
     the δ-opioid receptor and may be useful, inter alia, for treating
     and/or preventing pain, anxiety, gastrointestinal disorders, and other
     δ-opioid receptor-mediated diseases, disorders, and/or conditions.
IT   131-28-2, Narceine
     RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
     (Biological study); USES (Uses)
```

(analgesic spirocyclic heterocyclic derivs.)
RN 131-28-2 CAPLUS
CN Benzoic acid, 6-[2-[6-[2-(dimethylamino)ethyl]-4-methoxy-1,3-benzodioxol-5-yl]acetyl]-2,3-dimethoxy- (CA INDEX NAME)



L7 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2007:1002809 CAPLUS
DOCUMENT NUMBER: 147:412977
TITLE: Isoandrographolide derivatives for inhibiting COX-2, TNF-α, and IL-6 expression
INVENTOR(S): Zhang, Huibin; Huang, Wenlong; Li, Jing; Zhou, Huiping
PATENT ASSIGNEE(S): China Pharmaceutical University, Peop. Rep. China
SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 26pp.
CODEN: CNXXEV
DOCUMENT TYPE: Patent
LANGUAGE: Chinese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 101028260	A	20070905	CN 2007-10019982	20070206
PRIORITY APPLN. INFO.:			CN 2007-10019982	20070206
OTHER SOURCE(S):	MARPAT 147:412977			

GI



I

AB The invention relates to application of substituted isoandrographolide derivs. in preparing COX-2 expression inhibitor, and/or TNF-α inhibitor and/or IL-6 inhibitor. The invention also relates to general formula I of substituted isoandrographolide derivative, wherein R1 is H, hydroxy, C1-C8 linear or branched-chain alkoxy, C1-C8 linear or branched-chain alkanoyl, C1-C8 linear or branched-chain halogenated alkanoyl, C1-C8 linear or branched-chain halogenated alkoxy, substituted or unsubstituted aryloxy, substituted or unsubstituted arylacyl, substituted or unsubstituted heterocyclic aryloxy, or substituted or unsubstituted heterocyclic arylacyl; R2 is hydroxy, C1-C8 linear or branched-chain alkoxy, C1-C8

linear or branched-chain alkanoyl, C1-C8 linear or branched-chain halogenated alkanoyl, C1-C8 linear or branched-chain halogenated alkoxy, substituted or unsubstituted aryloxy, substituted or unsubstituted arylacyl, substituted or unsubstituted heterocyclic aryloxy, or substituted or unsubstituted heterocyclic arylacyl or R1 and R2 form hexaat. ring contains C and O; R3 is formula 2 or 3 on Pg2 wherein X is O, S, N or NR4; R4 is H, C1-C8 linear or branched-chain alkoxy, C1-C8 linear or branched-chain alkanoyl, C1-C8 linear or branched-chain halogenated alkanoyl, C1-C8 linear or branched-chain halogenated alkoxy, C1-C8 linear or branched-chain halogenated alkyl, C1-C8 linear or branched-chain alkyl, substituted or unsubstituted aryloxy, substituted or unsubstituted arylacyl, substituted or unsubstituted heterocyclic aryloxy, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted hetero. The substituting group in the above substitution groups is hydroxy, C1-C8 linear or branched-chain aryl, C1-C8 linear or branched-chain heteroaryl, C1-C8 linear or branched-chain alkoxy, C1-C8 linear or branched-chain alkanoyl, C1-C8 linear or branched-chain halogenated alkanoyl, C1-C8 linear or branched-chain halogenated alkoxy,, halogen, nitro or amino. TNF-α inhibitor can treat rheumatoid arthritis, juvenile rheumatoid arthritis, bony arthritis, spinal arthritis, inflammatory intestinal diseases, heart failure, diabetes mellitus, systemic lupus erythematosus, cancer, infectious shock, asthma, respiratory viral infection, obesity, etc. IL-6 inhibitor can treat Alzheimer's disease, schizophrenia, cancer, gouty arthritis, diabetes mellitus, depression and/or ankylosing spinal disease. COX-2 inhibitor can treat cancer, tumor multidrug resistance, thrombosis, myocardial ischemic anoxia, cerebrovascular disease, atherosclerosis, epilepsy, Parkinson's diseases and/or Alzheimer's disease.

IT 950895-56-4P
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(isoandrographolide derivs. for inhibiting COX-2, TNF-α, and IL-6 expression)

RN 950895-56-4 CAPLUS

CN Benzoic acid, 2-acetyl-, (3aR,5aS,6R,7R,9aR,9bS)-6-[[(2-acetylbenzoyl)oxy]methyl]-2-(2,5-dihydro-2-oxo-3-furanyl)dodecahydro-3a,6,9a-trimethylnaphtho[2,1-b]furan-7-yl ester (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 3 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2006:735083 CAPLUS
DOCUMENT NUMBER: 145:167261

TITLE: Preparation of 2-phenoxy-N-(1,3,4-thiadiazol-2-yl)pyridin-3-amine derivatives and related compounds as P2Y1 receptor inhibitors for the treatment of thromboembolic disorders

INVENTOR(S): Sutton, James C.; Pi, Zulan; Ruel, Rejean; L'Heureux, Alexandre; Thibeault, Carl; Lam, Patrick Y. S.

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 295 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006078621	A2	20060727	WO 2006-US1535	20060117
WO 2006078621	A3	20061005		
WO 2006078621	A9	20080619		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
AU 2006206611	A1	20060727	AU 2006-206611	20060117
US 20060173002	A1	20060803	US 2006-333050	20060117
JP 2008527043	T	20080724	JP 2007-552205	20060117
EP 1954696	A2	20080813	EP 2006-733718	20060117
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, HR, MK				
MX 2007008434	A	20070725	MX 2007-8434	20070711
NO 2007003665	A	20071018	NO 2007-3665	20070717
IN 2007DN05767	A	20070817	IN 2007-DN5767	20070725
KR 2007100894	A	20071012	KR 2007-718794	20070817
CN 101142212	A	20080312	CN 2006-80008886	20070919

PRIORITY APPLN. INFO.:

US 2005-645285P	P	20050119
US 2005-749317P	P	20051209
WO 2006-US1535	W	20060117

OTHER SOURCE(S): MARPAT 145:167261

GI



I II

AB Title compds. I [A = (un)substituted 5-6 membered heteroaryl; X = NH or NMe; Y = O or S; R1 = (un)substituted carbocycle or heterocycle], and their pharmaceutically acceptable salts, are prepared and disclosed as selective inhibitors of the human P2Y1 receptor. Thus, e.g., II was prepared by conversion of 2-(2-tert-butylphenoxy)-3-aminopyridine (preparation given) to the isothiocyanate derivative, then the thiosemicarbazide derivative which undergoes cyclocondensation with benzoyl chloride. I in P2Y1 binding assays have demonstrated Ki values of ≤ 10 μM, thereby confirming they act to modulate P2Y1 activity. The invention also provides for various pharmaceutical compns. of the same and methods for treating diseases responsive to modulation of P2Y1 receptor activity.

IT 133993-34-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of 2-phenoxy-N-(1,3,4-thiadizol-2-yl)pyridin-3-amine derivs. and related compound as P2Y1 receptor inhibitors for the treatment of thromboembolic disorders)

RN 133993-34-7 CAPLUS
CN Benzoic acid, 2-(2-bromoacetyl)-, ethyl ester (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:962245 CAPLUS
DOCUMENT NUMBER: 143:266938
TITLE: Preparation of fused pyridazine compounds as NAD(P)H oxidase inhibitors
INVENTOR(S): Seki, Maki; Tarao, Yoshihiro; Yamada, Kumi; Nakao, Akira; Usui, Yoshihiro; Komatsu, Yoshiyuki
PATENT ASSIGNEE(S): Mitsubishi Pharma Corporation, Japan
SOURCE: PCT Int. Appl., 105 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005080378	A1	20050901	WO 2005-JP2974	20050224

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,

RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: JP 2004-47129 A 20040224

OTHER SOURCE(S): MARPAT 143:266938

GI



I



II

AB Title compds. I [Het = (un)saturated 5-membered heterocycle containing at least one N atom; further details on Het are given.; ring A = II, etc.; B = H, halo, etc.; R4 = H, halo, etc.; l = 0-2; X = O, S] were prepared For example, aromatic nucleophilic substitution of 1-chloro-4-(1-methyl-1H-imidazol-2-yl)phthalazine, e.g., prepared from phthalic anhydride in 3 steps, with MeOH in the presence of NaH followed by treatment of HCl afforded 1-methoxy-4-(1-methyl-1H-imidazol-2-yl)phthalazine hydrochloride (III). In NAD(P)H oxidase inhibition assays (in vitro), compound III showed the inhibitory activity of 91%. Compds. I are claimed useful for the treatment of myocardial infarction, arteriosclerosis, etc.

IT 577-56-0, 2-Acetylbenzoic acid
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of fused pyridazine compds. as NAD(P)H oxidase inhibitors for treatment of myocardial infarction, arteriosclerosis, etc.)

RN 577-56-0 CAPLUS

CN Benzoic acid, 2-acetyl- (CA INDEX NAME)



IT 203124-56-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of fused pyridazine compds. as NAD(P)H oxidase inhibitors for treatment of myocardial infarction, arteriosclerosis, etc.)

RN 203124-56-5 CAPLUS

CN Benzoic acid, 2-(2,2,2-trifluoroacetyl)- (CA INDEX NAME)



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:450920 CAPLUS
DOCUMENT NUMBER: 142:482324
TITLE: Preparation of phenylalanine derivatives as δ-opioid receptor ligands
INVENTOR(S): Dolle, Roland E.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 34 pp., Cont.-in-part of U.S. Ser. No. 719,627.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050113295	A1	20050526	US 2004-991785	20041118
US 20050113294	A1	20050526	US 2003-719627	20031121

PRIORITY APPLN. INFO.: US 2003-719627 A2 20031121
OTHER SOURCE(S): CASREACT 142:482324; MARPAT 142:482324
GI



I

AB The invention relates to carboxamide and amino derivs. I [R1, R2 are independently H, alkyl, alkenyl or one of these is C(:NH)NH2, or R1R2N is heterocycloalkyl; R3 is -[J]0-16X (J is an aminoacyl residue, X is OH, alkoxy or an amino group), a peptide or substituted 2-isoquinolyl residue; R4-R7 are H or alkyl or NR6R7 is heterocycloalkyl; m is 0 or 1], including stereoisomers, prodrugs, and pharmaceutically-acceptable salts, which are ligands of the δ-opioid receptor and are useful, inter alia, for treating and/or preventing pain, anxiety, gastrointestinal disorders, and

other δ-opioid receptor-mediated conditions. Thus, (S)-2-amino-3-(4-carboxamidophenyl)propionic acid-Gly-Gly-Phe-Leu-NH2 was prepared by the solid-phase method and shown to possess Ki = 7 nM and EC50 = 74 nM against the δ receptor with greater than 10-fold selectivity vs. the μ and κ opioid receptors.

IT 131-28-2, Narceine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(claimed pharmaceutical agent; preparation of phenylalanyl peptides as δ-opioid receptor ligands)

RN 131-28-2 CAPLUS

CN Benzoic acid, 6-[2-[6-[2-(dimethylamino)ethyl]-4-methoxy-1,3-benzodioxol-5-yl]acetyl]-2,3-dimethoxy- (CA INDEX NAME)



L7 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:450919 CAPLUS

DOCUMENT NUMBER: 142:482323

TITLE: Preparation of phenylalanine derivatives as δ-opioid receptor ligands

INVENTOR(S): Dolle, Roland E.

PATENT ASSIGNEE(S): Adolor Corporation, USA

SOURCE: U.S. Pat. Appl. Publ., 32 pp.
CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050113294	A1	20050526	US 2003-719627	20031121
US 20050113295	A1	20050526	US 2004-991785	20041118
WO 2005051367	A1	20050609	WO 2004-US38656	20041118

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2003-719627 A2 20031121

OTHER SOURCE(S): MARPAT 142:482323

GI



I

AB The invention relates to carboxamide and amino derivs. I [R1, R2 are independently H, alkyl, alkenyl or one of these is C(:NH)NH2, or R1R2N is heterocycloalkyl; R3 is -[J]0-16X (J is an aminoacyl residue, X is OH, alkoxy or an amino group), a peptide or substituted 2-isoquinolyl residue; R4-R7 are H or alkyl or NR6R7 is heterocycloalkyl; m is 0 or 1], including stereoisomers, prodrugs, and pharmaceutically-acceptable salts, which are ligands of the δ-opioid receptor and are useful, inter alia, for treating and/or preventing pain, anxiety, gastrointestinal disorders, and other δ-opioid receptor-mediated conditions. Thus, (S)-2-amino-3-(4-carboxamidophenyl)propionic acid-Gly-Gly-Phe-Leu-NH2 was prepared by the solid-phase method and shown to possess Ki = 7 nM and EC50 = 74 nM against the δ receptor with greater than 10-fold selectivity vs. the μ and κ opioid receptors.

IT 131-28-2, Narceine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(claimed pharmaceutical agent; preparation of phenylalanyl peptides as δ-opioid receptor ligands)

RN 131-28-2 CAPLUS

CN Benzoic acid, 6-[2-[6-[2-(dimethylamino)ethyl]-4-methoxy-1,3-benzodioxol-5-yl]acetyl]-2,3-dimethoxy- (CA INDEX NAME)



L7 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:238692 CAPLUS

DOCUMENT NUMBER: 142:316849

TITLE: Preparation of phthalazinones as PARP inhibitors

INVENTOR(S): Martin, Niall Morrison Barr; Smith, Graeme Cameron; Jackson, Stephen Philip; Loh, Vincent M., Jr.; Cockcroft, Xiao-Ling Fan; Matthews, Ian Timothy Williams; Menear, Keith Allan; Kerrigan, Frank; Ashworth, Alan

PATENT ASSIGNEE(S): Kudos Pharmaceuticals Limited, UK; Maybridge Limited

SOURCE: U.S. Pat. Appl. Publ., 67 pp., Cont.-in-part of U.S. Ser. No. 799,154.
CODEN: USXXCO

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 20050059663	A1	20050317	US 2004-876080		20040624
US 7449464	B2	20081111			
ZA 2005007097	A	20060628	ZA 2005-7097		20050905
US 20060149059	A1	20060706	US 2005-318155		20051223
JP 2008001718	A	20080110	JP 2007-226723		20070831
US 20080200469	A1	20080821	US 2008-109260		20080424
PRIORITY APPLN. INFO.:			GB 2003-5681	A	20030312
			US 2003-454995P	P	20030314
			US 2003-493399P	P	20030806
			US 2003-526244P	P	20031201
			US 2004-799154	A2	20040312
			JP 2006-505955	A3	20040312
			US 2004-876080	A3	20040624

OTHER SOURCE(S): CASREACT 142:316849; MARPAT 142:316849
GI



AB The title compds. [I; A and B together represent (un)substituted fused aromatic ring; X = NRx or CRxRy; if X= NRx then n = 1 or 2 and if X = CRxRy then n = 1; Rx = H, (un)substituted C1-20 alkyl, C5-20 aryl, C3-20 heterocyclyl, amido, thioamido, ester, acyl, and sulfonyl groups; Ry = H, OH, NH2; or Rx and Ry may together form a spiro(C3-7)cycloalkyl or heterocyclyl group; R11 and R12 are both H, or when X = CRxRy, R11, R12, Rx and Ry, together with the carbon atoms to which they are attached, may form (un)substituted fused aromatic ring; R1 = H, halo], were prepared Thus, reacting 3-(4-oxo-3,4-dihydrophthalazin-1-ylmethyl)benzoic acid (preparation given) with tert-Bu 1-piperazinecarboxylate afforded 77% II which had IC50 of < 0.02 μM against PARP. All compds. I tested had a IC50 of < 0.1 μM in the PARP assay. The pharmaceutical composition comprising the compound I is claimed.

IT 763114-24-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of phthalazinones as PARP inhibitors for use in the treatment of cancer which is deficient in HR dependent DNA DSB repair pathway)

RN 763114-24-5 CAPLUS
CN Benzoic acid, 2-[2-(3-carboxyphenyl)acetyl]- (CA INDEX NAME)



REFERENCE COUNT: 261 THERE ARE 261 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 8 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:780675 CAPLUS
DOCUMENT NUMBER: 141:296034
TITLE: Preparation of phthalazinones as PARP inhibitors
INVENTOR(S): Martin, Niall Morrison Barr; Smith, Graeme Cameron Murray; Jackson, Stephen Philip; Loh, Vincent M., Jr.; Cockcroft, Xiao-Ling Fan; Matthews, Ian Timothy Williams; Menear, Keith Allan; Kerrigan, Frank; Ashworth, Alan
PATENT ASSIGNEE(S): Kudos Pharmaceuticals Limited, UK; Maybridge Limited
SOURCE: PCT Int. Appl., 102 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004080976	A1	20040923	WO 2004-GB1059	20040312
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004220321	A1	20040923	AU 2004-220321	20040312
CA 2517629	A1	20040923	CA 2004-2517629	20040312
GB 2415430	A	20051228	GB 2005-20754	20040312
GB 2415430	B	20060712		
BR 2004008284	A	20060307	BR 2004-8284	20040312
EP 1633724	A1	20060315	EP 2004-720068	20040312
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
CN 1788000	A	20060614	CN 2004-80012878	20040312
JP 2006519827	T	20060831	JP 2006-505955	20040312
JP 4027406	B2	20071226		
NZ 542680	A	20080829	NZ 2004-542680	20040312
IN 2005DN03895	A	20070427	IN 2005-DN3895	20050831
ZA 2005007097	A	20060628	ZA 2005-7097	20050905
MX 2005009661	A	20060308	MX 2005-9661	20050909
KR 2006054172	A	20060522	KR 2005-716883	20050909
NO 2005004625	A	20051111	NO 2005-4625	20051007
HK 1079530	A1	20061020	HK 2006-101301	20060127

JP 2008001718	A	20080110	JP 2007-226723		20070831
PRIORITY APPLN. INFO.:			GB 2003-5681	A	20030312
			US 2003-454995P	P	20030314
			US 2003-493399P	P	20030806
			US 2003-526244P	P	20031201
			JP 2006-505955	A3	20040312
			WO 2004-GB1059	A	20040312

OTHER SOURCE(S): MARPAT 141:296034

GI



I



II

AB The title compds. [I; A and B together represent (un)substituted fused aromatic ring; X = NRx or CRxRy; if X= NRx then n = 1 or 2 and if X = CRxRy then n = 1; Rx = H, (un)substituted C1-20 alkyl, C5-20 aryl, C3-20 heterocyclyl, amido, thioamido, ester, acyl, and sulfonyl groups; Ry = H, OH, NH2; or Rx and Ry may together form a spiro(C3-7)cycloalkyl or heterocyclyl group; R11 and R12 are both H, or when X = CRxRy, R11, R12, Rx and Ry, together with the carbon atoms to which they are attached, may form (un)substituted fused aromatic ring; R1 = H, halo], were prepared Thus, reacting 3-(4-oxo-3,4-dihydrophthalazin-1-ylmethyl)benzoic acid (preparation given) with tert-Bu 1-piperazinecarboxylate afforded 77% II which had IC50 of < 0.02 μM against PARP. All compds. I tested had a IC50 of < 0.1 μM in the PARP assay. The pharmaceutical composition comprising the compound I is claimed.

IT 763114-24-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of phthalazinones as PARP inhibitors)

RN 763114-24-5 CAPLUS

CN Benzoic acid, 2-[2-(3-carboxyphenyl)acetyl]- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:335110 CAPLUS

DOCUMENT NUMBER: 138:338296

TITLE: Preparation of phosphonic acid compounds as inhibitors

of serine proteases

INVENTOR(S): Greco, Michael N.; Almond, Harold R.; De Garavilla, Lawrence; Hawkins, Michael J.; Maryanoff, Bruce E.; Qian, Yun; Walker, Donald Gilmore; Cesco-Cancian, Sergio; Nilsen, Christopher Norman; Patel, Mitul N.; Humora, Michael J.

PATENT ASSIGNEE(S): Ortho-McNeil Pharmaceutical, Inc., USA

SOURCE: PCT Int. Appl., 110 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2003035654	A1	20030501	WO 2002-US33206		20021017
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2464111	A1	20030501	CA 2002-2464111		20021017
AU 2002356818	A1	20030506	AU 2002-356818		20021017
AU 2002356818	B2	20090226			
EP 1438316	A1	20040721	EP 2002-802153		20021017
EP 1438316	B1	20060621			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK					
BR 2002013961	A	20040831	BR 2002-13961		20021017
CN 1604904	A	20050406	CN 2002-825098		20021017
JP 2005537217	T	20051208	JP 2003-538169		20021017
AT 330961	T	20060715	AT 2002-802153		20021017
HU 2006000339	A2	20060828	HU 2006-339		20021017
ES 2266634	T3	20070301	ES 2002-802153		20021017
NZ 532372	A	20070727	NZ 2002-532372		20021017
RU 2311421	C2	20071127	RU 2004-111784		20021017
MX 2004003707	A	20050408	MX 2004-3707		20040419
IN 2004KN00625	A	20060421	IN 2004-KN625		20040513
NO 2004002057	A	20040518	NO 2004-2057		20040518
ZA 2004003824	A	20050913	ZA 2004-3824		20040518
HK 1065802	A1	20061124	HK 2004-108770		20041108
PRIORITY APPLN. INFO.:			US 2001-330343P	P	20011019
			WO 2002-US33206	W	20021017

OTHER SOURCE(S): CASREACT 138:338296; MARPAT 138:338296

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Phosphonic acid compds. [I; wherein R1 = (substituted) heterocyclic ring with the point of attachment being a nitrogen ring atom, amino; R2, R3, independently = H, (C1-C4)alkyl, (C1-C4)alkoxy, (C2-C4)alkenyl, amino, halo, hydroxy, or R2 and R3 together form at least one ring fused to the benzene ring; R4 = (C1-C4)alkyl, aryl, heteroaryl; R5 = H, (C1-C8)alkyl;

R6 = (C1-C8)alkyl, aryl(C1-C8)alkyl, (C1-C8)alkoxy, aryl(C1-C8)alkoxy, (C2-C8)alkenyloxy, etc.; X, Y, independently = H, (C1-C8)alkyl, (C1-C8)alkoxy, (C2-C8)alkenyloxy, cycloalkyl, heterocyclyl, aryl, aryloxy, etc.; Z = a bond, H, (C1-C8)alkyl] were prepared For example, compound (II) was prepared in several steps. The prepared compds. are useful as serine protease inhibitors and, thus, are useful for treating inflammatory and serine protease mediated disorders. For example, compound II showed good inhibition against cathepsin G (IC50 = .081 μM).

IT 429676-95-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of phosphonic acid compds. as inhibitors of serine proteases)

RN 429676-95-9 CAPLUS

CN 2-Naphthalenecarboxylic acid, 3-[2-(diethoxyphosphinyl)-2-(1-naphthalenyl)acetyl]- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:716126 CAPLUS

DOCUMENT NUMBER: 137:252985

TITLE: Medicinal compositions containing bile acid transporter inhibitor and cholesterol acyltransferase inhibitors

INVENTOR(S): Inaba, Toshimori

PATENT ASSIGNEE(S): Sankyo Company, Limited, Japan

SOURCE: PCT Int. Appl., 70 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002072147	A1	20020919	WO 2002-JP2311	20020312
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002236307	A1	20020924	AU 2002-236307	20020312
JP 2002338496	A	20021127	JP 2002-67841	20020313

PRIORITY APPLN. INFO.: JP 2001-72050 A 20010314

WO 2002-JP2311 W 20020312

AB Disclosed are medicinal compns. for administering an ileal bile acid transporter inhibitor and a cholesterol acyltransferase (ACAT) inhibitor either at the same time or sep. at a certain interval. The effect of oral administration of both 4-[3-[(1-(3,5-difluorophenyl)ethylamino)-(4-methoxyphenyl)methyl]phenylamino]-3-hydroxy-3-cyclobutene-1,2-dione (I) and N-(1-octyl-5-carboxymethyl-4,6-dimethylindoline-7-yl)-2,2-dimethylpropaneamide (II) on blood serum triglyceride was prepared Also, a tablet containing I 50, II 30, lactose 368, corn starch 50, magnesium stearate 2 mg was prepared

IT 151165-96-7, S-8921
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hypolipemic compns. containing bile acid transporter inhibitor and cholesterol acyltransferase inhibitors)

RN 151165-96-7 CAPLUS

CN 2-Naphthalenecarboxylic acid, 1-(3,4-dimethoxyphenyl)-3-(3-ethyl-1-oxopentyl)-4-hydroxy-6,7,8-trimethoxy-, methyl ester (CA INDEX NAME)



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 11 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1999:819369 CAPLUS
DOCUMENT NUMBER: 132:49958
TITLE: Preparation of pyrazolopyridine derivatives as adenosine antagonists
INVENTOR(S): Akahane, Atsushi; Nishimura, Shintaro; Kuroda, Satoru; Itani, Hiromichi
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 92 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9967239	A1	19991229	WO 1998-JP2794	19980622
W: CA, CN, JP, KR, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
PRIORITY APPLN. INFO.:			WO 1998-JP2794	19980622

OTHER SOURCE(S): MARPAT 132:49958
GI



I

AB The title compds. I [R = alkanoylalkyl, etc.] are prepared These compds. are adenosine antagonists and useful as recognition augmenters, nootropic drugs, mental stimulants, analgesic agents, cardiac protective drugs, antidepressive drugs, cerebral vasodilators, tranquilizers, remedies for cardiac failure, cardiac tonics, hypotensive drugs, drugs for renal insufficiency, remedies for nephrotoxicity, renal protective agents, renal function improving drugs, diuretic agents, remedies for edema, antiobesic drugs, antiasthmatics, bronchodilators, remedies for apnea, remedies for gout, remedies for hyperuricemia, remedies for sudden infant death syndrome (SIDS), drugs for improving immunosuppression by adenosine, antidiabetic drugs, antiulcer drugs, remedies for pancreatitis, remedies for Meniere syndrome, antianemic agents, remedies for thrombosis, remedies for heart infarction, remedies for embolism, remedies for arteriosclerosis obliterans, remedies for thrombotic phlebitis, remedies for brain infarction, remedies for transient cerebral ischemia, remedies for angina pectoris, etc. In an in vitro test for adenosine A1 antagonism, 3-[2-(1-methyl-2-oxopropyl)-3-oxo-2,3-dihydrpyridazine-6-yl]-2-phenylpyrazolo[1,5-a]pyridine at 3.2 X 10-7 M showed > 90% inhibition of binding of [3H]-N6-cyclohexyladenosine.

IT 210879-79-1P 210879-99-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazolopyridine derivs. as adenosine antagonists)

RN 210879-79-1 CAPLUS
CN Benzoic acid, 2-[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]acetyl]-, methyl ester (CA INDEX NAME)



RN 210879-99-5 CAPLUS
CN Benzoic acid, 2-[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]acetyl]- (CA INDEX NAME)



IT 577-56-0, 2-Acetylbenzoic acid
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of pyrazolopyridine derivs. as adenosine antagonists)
RN 577-56-0 CAPLUS
CN Benzoic acid, 2-acetyl- (CA INDEX NAME)



IT 7460-55-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrazolopyridine derivs. as adenosine antagonists)
RN 7460-55-1 CAPLUS
CN Benzoic acid, 2-(2-bromoacetyl)-, methyl ester (CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 12 OF 12 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1993:191726 CAPLUS
DOCUMENT NUMBER: 118:191726
ORIGINAL REFERENCE NO.: 118:32941a,32944a
TITLE: Preparation oxazole and thiazole derivatives as active oxygen inhibitors
INVENTOR(S): Chihiro, Masatoshi; Komatsu, Hajime; Tominaga, Michiaki; Yabuuchi, Youichi
PATENT ASSIGNEE(S): Otsuka Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 560 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 9209586	A1	19920611	WO 1991-JP1659	19911129
W: AU, CA, KR, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
CA 2074933	A1	19920531	CA 1991-2074933	19911129
CA 2074933	C	20021203		
AU 9189367	A	19920625	AU 1991-89367	19911129
AU 656930	B2	19950223		
CA 2396738	A1	19920625	CA 1991-2396738	19911129
CA 2396738	C	20060829		
CA 2547947	A1	19920625	CA 1991-2547947	19911129
CA 2547947	C	20070925		
EP 513387	A1	19921119	EP 1991-920815	19911129
EP 513387	B1	20000301		
R: CH, DE, DK, ES, FR, GB, IT, LI, NL, SE				
JP 05051318	A	19930302	JP 1991-342495	19911129
EP 934937	A1	19990811	EP 1999-107493	19911129
EP 934937	B1	20020227		
R: CH, DE, DK, ES, FR, GB, IT, LI, NL, SE				
ES 2144403	T3	20000616	ES 1991-920815	19911129
EP 1130017	A2	20010905	EP 2001-112988	19911129
EP 1130017	A3	20010919		
EP 1130017	B1	20050615		
R: CH, DE, DK, ES, FR, GB, IT, LI, NL, SE				
ES 2173683	T3	20021016	ES 1999-107493	19911129
ES 2245660	T3	20060116	ES 2001-112988	19911129
US 5643932	A	19970701	US 1995-444728	19950519
US 5677319	A	19971014	US 1995-482657	19950607
US 6080764	A	20000627	US 1997-826343	19970325
JP 10101562	A	19980421	JP 1997-233370	19970813
JP 3182556	B2	20010703		
HK 1003938	A1	20000721	HK 1998-103139	19980416
US 37556	E1	20020219	US 1999-245914	19990208

PRIORITY APPLN. INFO.:	JP 1990-337727	A	19901130
	CA 1991-2074933	A3	19911129
	CA 1991-2396738	A3	19911129
	EP 1991-920815	A3	19911129
	EP 1999-107493	A3	19911129
	JP 1991-342495	A3	19911129
	WO 1991-JP1659	A	19911129
	US 1992-916082	B1	19920729
	US 1995-444728	A3	19950519
	US 1995-482657	A3	19950607

OTHER SOURCE(S): MARPAT 118:191726

GI



I



Q



II



@ HCl

III

AB The title compds. [I; R1 = (substituted) Ph; R2 = H, halo, alkyl, Ph alkoxycarbonyl, alkylamino, etc.; R3 = Q (wherein R = OH, CO2H, alkyl, alkenyl; m = 0-2); X = S, O], useful in treating thrombosis, arteriosclerosis, peptic ulcers, etc., are prepared A suspension of 367 mg II and 430 mg 3,4-(MeO)2C6H3CSNH2 in EtOH was refluxed to give 160 mg thiazole salt III, which showed IC50 of 1 μM against superoxide formation. I were also effective in treating arrhythmia, ischemic renal disorders, and myocardial necrosis.

IT 145736-88-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, in preparation of active oxygen inhibitor)

RN 145736-88-5 CAPLUS

CN Benzoic acid, 2-(2-bromoacetyl)-6-nitro-, methyl ester (CA INDEX NAME)



REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> logoff
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	73.16	259.26

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-9.84	-9.84

STN INTERNATIONAL LOGOFF AT 11:22:16 ON 06 APR 2009